PRESTON ROMM JOINS SUNEVA MEDICAL AS CHIEF OPERATING OFFICER

  • Former Obagi Medical Products and Valeant Pharmaceuticals executive brings decades of experience to dynamic aesthetics company
  • Appointment strengthens Suneva Medical’s executive team and accelerates its vision to become a leader in the cash-pay aesthetics market
  • Romm will be responsible for the company’s sales, marketing and operations business functions

San Diego, CA (June 16, 2016)—Suneva Medical, Inc., a privately-held aesthetics company, today announced the appointment of Preston Romm to chief operating officer (COO). Romm joins Suneva Medical with more than 30 years of experience and will be responsible for leading the company’s sales, marketing and operations. Previously serving as president of Obagi Medical Products and senior vice president of Valeant Pharmaceuticals, Romm brings a rich background in the facial aesthetic industry and will be an instrumental executive on Suneva Medical’s leadership team.

Preston Romm Headshot Cropped“Preston’s impressive track record and deep rooted experience in facial aesthetics is a welcomed addition,” said Nicholas L. Teti, Jr., Chairman and Chief Executive Officer at Suneva Medical. “As we enter another significant growth phase at Suneva, he will play a critical role in further elevating our position as an innovative aesthetics player that is committed to exceptional results and enduring patient satisfaction.”

Romm’s decades of senior leadership experience spans finance, marketing, sales, operations and administration. Throughout his career, he has been responsible for overseeing financing growth strategies, negotiating and integrating mergers and acquisitions, supply chain management processes, ERP systems, internal controls and Sarbanes-Oxley compliance procedures. Romm holds an MBA from American University and a B.S. in Accounting from the University of Maryland.

“Joining Suneva is a tremendous opportunity and I look forward to advancing its position within the general dermatology and aesthetic markets,” said Romm. “In a short time, the company has built a strong business foundation and it will be my top priority to strengthen opportunities within its operations, sales and marketing teams.”

For more information on Suneva Medical, visit www.sunevamedical.com/old.

About Suneva Medical, Inc.

Suneva Medical is a privately-held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the general dermatology and aesthetic markets. The innovative aesthetics leader markets Bellafill®, the only dermal filler on the market that is approved by the U.S. Food and Drug Administration for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. The company markets Bellafill® in the U.S., Canada and Hong Kong; ArteFill® in South Korea; Regenica® skin care in the U.S., Canada and Hong Kong; and ReFissa® tretinoin cream in the U.S. ArteFill® was rebranded to Bellafill® in the U.S. to reflect the transformational outcomes this unique product can provide to patients seeking correction of their acne scars and nasolabial folds. For more information, visit www.sunevamedical.com/old.

 

Important Safety Information

Bellafill®
Bellafill® is indicated for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. Patients who have had a positive reaction to the Bellafill® Skin Test, have a history of severe allergies, have known bovine collagen allergies, are allergic to lidocaine, have bleeding disorders or are prone to thick scar formation and/or excessive scarring should not receive Bellafill®. The safety of Bellafill® for use during pregnancy, breastfeeding, or in patients under 21 has not been established. You may experience temporary swelling, redness, pain, bruising, lumps/bumps, itching, and discoloration at the treatment site. These side effects are usually transient and typically resolve within 1–7 days. You may experience lumps/bumps/papules that may occur more than one month after injection and that may persist. Less common side effects include rash and itching more than 48 hours after treatment, persistent swelling or redness, lumps/bumps, acne, and increased sensitivity at treatment sites. Infrequently, granulomas may occur and may be treated by your licensed physician provider. Be sure to call your licensed provider immediately if you notice any unusual skin reactions around the treatment area. Based on the 5-year Post-Approval Study on nasolabial folds with 1,008 patients, long-term safety of Bellafill® for up to 5 years has been established.

PUREGRAFT
This product is certified as a medical device in the European Union under the Medical Device Directive 93/42/EEC by SGS CE0120, exclusively for the indication of autologous fat transfer. Other non-medical uses ascribed to this device such as aesthetic body contouring are not within the scope of CE certification, and users should be aware product performance and/or safety has not been evaluated by SGS for those purposes.

Suneva Medical HD PRP
REGULATORY STATUS: FDA-cleared 510(k) Class II medical device. Healeon HD PRP is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of peripheral blood at the patient point of care. The PRP is mixed with autograft and/orallograft bone prior to application to a bony defect for improving handling characteristics. 510(k) number: BK170136

Silhouette Instalift
Silhouette lnstaLift® is indicated for use in mid-face suspension surgery to temporarily fixate the cheek sub-dermis in an elevated position.

IMPORTANT SAFETY CONSIDERATIONS
The Silhouette InstaLift device should not be used in patients with any known allergy or foreign body sensitivities to plastic/ biomaterial or in situations where internal fixation is otherwise contraindicated, (e.g. infection.) The device should also not be used in patients appearing to have very thin soft tissue of the face in which the implant may be visible or palpable.

Like all procedures of this type there is a possibility of adverse events, although not everybody experiences them. These adverse events include but are not limited to infection, minimal acute inflammatory tissue reaction, pain (which may be temporary or persistent in nature), swelling and edema, transient hematoma or bruising and transient rippling or dimple formation. For further safety or product information, please consult your physician.

For more safety information, please consult with your physician and the patient labeling that can be found by visiting our website www.bellafill.com.
Toll-free call (U.S. & Canada): 844-Bellafill (844-235-5234).
Local calls: 858-550-9999. International calls: ++ 858-550-9999.